Cited 2 times in

Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer

DC Field Value Language
dc.contributor.authorKim, SW-
dc.contributor.authorNoh, OK-
dc.contributor.authorKim, JH-
dc.contributor.authorChun, M-
dc.contributor.authorOh, YT-
dc.contributor.authorKang, SY-
dc.contributor.authorLee, HW-
dc.contributor.authorPark, RW-
dc.contributor.authorYoon, D-
dc.date.accessioned2018-08-24T01:48:22Z-
dc.date.available2018-08-24T01:48:22Z-
dc.date.issued2017-
dc.identifier.issn0344-5704-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15835-
dc.description.abstractPURPOSE: We aimed to present the clinical outcomes of adjuvant concurrent chemoradiotherapy (CCRT) with low-dose daily cisplatin regimen compared to the conventional 5-fluorouracil (5-FU)-based regimen for extrahepatic bile duct cancer (EHBDC).
METHODS: From October 1994 to April 2013, 41 patients received adjuvant CCRT with low-dose daily regimen or 5-FU-based regimens. Nineteen patients received low-dose of cisplatin just before every delivery of radiation therapy, and 21 patients received two cycles of 5-FU-based regimen during radiotherapy. We compared the clinical outcomes between two adjuvant CCRT regimens.
RESULTS: Adjuvant CCRT with low-dose daily cisplatin showed comparable toxicity profiles compared with that of a 5-FU-based regimen. The median follow-up time was 33 months (range, 5-205), and the 5-year overall survival (OS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) were 34.2, 50.8, and 49.7%, respectively. Univariable analyses showed no significant differences in OS, LRRFS, and DMFS between the groups with two regimens. In multivariable analyses, chemotherapeutic regimen was a significant prognostic factor for OS, favoring the low-dose daily cisplatin regimen (HR = 2.491, p = 0.036) over 5-FU-based regimen, though not for LRRFS (p = 0.642) and DMFS (p = 0.756).
CONCLUSIONS: Adjuvant CCRT with low-dose daily cisplatin regimen showed acceptable toxicities and survivals compared to those of the 5-FU-based regimen. Low-dose daily cisplatin can be one of the feasible regimens for adjuvant CCRT for EHBDC.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntimetabolites, Antineoplastic/therapeutic use-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHAntineoplastic Agents/adverse effects-
dc.subject.MESHAntineoplastic Agents/therapeutic use-
dc.subject.MESHBile Duct Neoplasms/drug therapy-
dc.subject.MESHBile Duct Neoplasms/radiotherapy-
dc.subject.MESHBile Duct Neoplasms/therapy-
dc.subject.MESHBile Ducts, Extrahepatic-
dc.subject.MESHChemoradiotherapy, Adjuvant/methods-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHCisplatin/adverse effects-
dc.subject.MESHCisplatin/therapeutic use-
dc.subject.MESHCombined Modality Therapy/adverse effects-
dc.subject.MESHComorbidity-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/therapeutic use-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrognosis-
dc.subject.MESHSurvival Analysis-
dc.titleAdjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer-
dc.typeArticle-
dc.identifier.pmid28447209-
dc.contributor.affiliatedAuthor노, 오규-
dc.contributor.affiliatedAuthor김, 지훈-
dc.contributor.affiliatedAuthor전, 미선-
dc.contributor.affiliatedAuthor오, 영택-
dc.contributor.affiliatedAuthor강, 석윤-
dc.contributor.affiliatedAuthor이, 현우-
dc.contributor.affiliatedAuthor박, 래웅-
dc.contributor.affiliatedAuthor윤, 덕용-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s00280-017-3312-y-
dc.citation.titleCancer chemotherapy and pharmacology-
dc.citation.volume79-
dc.citation.number6-
dc.citation.date2017-
dc.citation.startPage1161-
dc.citation.endPage1167-
dc.identifier.bibliographicCitationCancer chemotherapy and pharmacology, 79(6). : 1161-1167, 2017-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1432-0843-
dc.relation.journalidJ003445704-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Biomedical Informatics
Files in This Item:

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse